News
CERT
8.20
+0.86%
0.07
Certara Corrects EBITDA Disclosure in Earnings Presentation
TipRanks · 13h ago
Certara (CERT) Could Be 9% Undervalued On Earnings Guidance And Buyback News
Simply Wall St · 17h ago
Certara price target raised to $7 from $6 at Baird
TipRanks · 2d ago
Certara price target lowered to $9 from $10 at Morgan Stanley
TipRanks · 2d ago
Certara: Hold Rating Maintained as Turnaround Progress Offsets Near-Term Pressures; Price Target Trimmed from $10 to $9
TipRanks · 2d ago
BMO Capital Sticks to Its Hold Rating for Certara (CERT)
TipRanks · 2d ago
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5
Benzinga · 2d ago
Certara price target raised to $7.50 from $6.50 at Barclays
TipRanks · 3d ago
Barclays Sticks to Its Hold Rating for Certara (CERT)
TipRanks · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (ARVN), Certara (CERT) and Helus Pharma (HELP)
TipRanks · 3d ago
Certara (CERT) Q2 2026 Earnings Call Transcript
The Motley Fool · 3d ago
Certara (CERT) Stock Price Faces Loss Pressure Despite Software Gains
Simply Wall St · 3d ago
Certara Earnings Call: Software Strength Amid Services Strain
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Design Therapeutics (DSGN), Certara (CERT) and GeneDx Holdings (WGS)
TipRanks · 3d ago
How Certara’s Widening Losses Amid Modest Sales Growth Will Impact Certara (CERT) Investors
Simply Wall St · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (MD), Certara (CERT) and Gilead Sciences (GILD)
TipRanks · 3d ago
Transcript: Certara Q2 2026 Earnings Conference Call
Benzinga · 3d ago
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
NASDAQ · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is a provider of biosimulation science, technology, and consulting services for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical and biotech industry. The Company's proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body. It has developed scientifically-based solutions for the collection, standardization, validation, storage, and analysis of the preclinical, clinical and evidence data needed for MIDD. These data solutions are used internally and industry-wide by life sciences companies. The Company applies AI capabilities within established modeling environments and under the supervision of experienced scientists and regulatory experts. Its modeling platforms and curated datasets position it to incorporate emerging AI techniques in a controlled and scientifically rigorous manner.